RIGL
Rigel Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-03
Figures on this page computed 2026-11-08 12:40 UTC
Last close
51.29USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-03-03
1.9xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-03
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
n/mNet marginnet income exceeds revenue
Net income exceeds revenue.
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
- Growth22.1%89 of 100, above its sector
- Returns on capital93.8%99 of 100, above its sector
- Margins93.3%97 of 100, above its sector
- Price1.9x62 of 100, above its sector
- Safety2.4266 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Where the price sits
lens 6 of 9Its multiple of earnings
1.9x- Where it is now1.9x
- Its sector's middle26.9x
- The market's middle19.9x
Its own year, in the price it trades at
51.3Market data, 2026-11-04
Its price against earnings, set beside its own year, its sector and the market. A low multiple is cheap or it is broken, and this page does not claim to know which.
Its price against earnings, set beside its own year, its sector and the market. A low multiple is cheap or it is broken, and this page does not claim to know which.
Every figure in this lens
Price against earnings1.9x10-K for 2025, filed 2026-03-03
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
Last close51.3Market data, 2026-11-04
- Source
- market
- Taken on
- 2026-11-04
- Reported in
- USD